PharmaShots

APRIL 3, 2023

of the newly combined company The combined companies’ focus is to advance Elicio’s lymph node-targeting amphiphile technology to develop immunotherapies & also focus on ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors is currently being evaluated in the P-I trial (AMPLIFY-201) for PDAC and CRC. ORR (41.8%

FDA 40

FDA Compounding Hospitals Vaccines 40

ISPE

SEPTEMBER 11, 2023

Nature Communications 12, no. Worldwide Modular Facilities in Pharmaceutical and Biotechnology Industry to 2030 - Impact Analysis of COVID-19.” www.prnewswire.com/news-releases/worldwide-modular-facilities-in-pharmaceutical-and-biotechnology-industry-to-2030 impact-analysis-of-covid-19-301332565.html 3 (2020):e2970.

Health and Personal Care Stores 52

Health and Personal Care Stores Vaccines Packaging Documentation 52

Pharmaceutical Technology

MAY 26, 2023

Tripling its production capacity, Touchlight can now manufacture 8kg plasmid DNA, a key component for mRNA gene therapies and vaccines. Research into genetic medicines like mRNA vaccines and gene therapies, as well as gene-editing treatments and novel cancer therapies, have driven increased demand for DNA.

Vaccines 52

Vaccines Communication FDA 52